16 . Ahmed KA , Stallworth DG , Kim Y , et al . Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti- PD-1 therapy [ published online December 27 , 2015 ]. Ann Oncol . doi : 10.1093 / annonc / mdv622 .
17 . FDA medication guide for Intron A . Available at http :// www . fda . gov / downloads / Drugs / DrugSafety / ucm111337 . pdf
18 . Hanzly M , Aboumohamed A , Yarlagadda N , Creighton T , Digiorgio L , Fredrick A , Rao G , Mehedint D , George S , Attwood K , Kauffman E , Narashima D , Khushalani NI , Pili R , Schwaab T . High-dose interleukin-2 therapy for metastatic renal cell carcinoma : a contemporary experience . Urology 2014 ; 83:1129 – 34 .
19 . Nguyen T , Urban J , Kalinski P . Therapeutic cancer vaccines and combination immunotherapies involving vaccination . ImmunoTargets Ther 2014 ; 3:135 – 50 .
20 . Schlom J . Therapeutic cancer vaccines : current status and moving forward . J Natl Cancer Inst 2012 ; 104:599 – 613 .
21 . Calvo E , Lopez-Marin JA , Bendell J , et al . Nivolumab ( NIVO ) monotherapy or in combination with ipilimumab ( IPI ) for treatment of recurrent small cell lung cancer ( SCLC ). Presented at : 2015 European Cancer Congress ; September 25-29 ; Vienna , Austria . Abstract 3098 .
22 . Postow MA , Chesney J , Pavlick A , et al . nivolumab and ipilimumab versus ipilimumab in untreated melanoma . New Engl J Med 2015 ; 372:2006-2017 .
23 . Creelan BC . Update on immune checkpoint inhibitors in lung cancer . Cancer Control 2014 ; 21:80 – 9 .
24 . Mahoney KM , Freeman GJ , McDermott DF . The next immune-checkpoint inhibitors : PD-1 / PD-L1 blockade in melanoma . Clinical Therapeutics 2015 ; 37:764-782 .
25 . Blackburn , S . D . et al . Coregulation of CD8 + T cell exhaustion by multiple inhibitory receptors during chronic viral infection . Nature Immunol 2009 ; 10:29 – 37 .
26 . Grosso , J . F . et al . Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells . J . Immunol 2009 ; 182:6659 – 6669 .
27 . Kohrt HE , Thielens A , Marabelle A , et al . Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies . Blood 2014 ; 123:678-686
28 . Gauttier V , Judor JP , Le Guen V , Cany J , Ferry N , Conchon S . Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer . Int J Cancer 2014 ; 135:2857-2867 .
29 . Shindo Y , Yoshimura K , Kuramasu A , Watanabe Y , Ito H , Kondo T , Oga A , Ito H , Yoshino S , Hazama S , Tamada K , Yagita H , Oka M . Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor . Anticancer Res 2015 ; 35:129-36 .
30 . Kocak E , Lute K , Chang X , May KF Jr , Exten KR , Zhang H , Abdessalam SF , Lehman AM , Jarjoura D , Zheng P , Liu Y . Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity . Cancer Res 2006 ; 66:7276 .
31 . Shtivelman E . ASCO 2014 Lung Cancer Roundup . CancerCommons June 11 , 2014 . Available at : https :// www . cancercommons . org / 2014 / 06 / 11 / asco-2014-lung-cancer-round-up /
32 . Frederick DT , Piris A , Cogdill AP , Cooper ZA , Lezcano C , Ferrone CR , et al . BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma . Clin Cancer Res 2013 ; 19:1225- 1231 .
33 . Cooper ZA , et al . Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade . Cancer Immunol Res 2014 ; 2:643 – 654 .
34 . Amin , A . et al . Nivolumab ( anti-PD-1 ; BMS-936558 , ONO-4538 ) in combination with sunitinib or pazopanib in patients ( pts ) with metastatic renal cell carcinoma ( mRCC ). J Clin Oncol 2014 ; 32:5010 .
35 . Kim T , Amaria RN , Spencer C , Reuben A , Cooper ZA , Wargo JA . Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma . Cancer Biol Med 2014 ; 11:237-246 .
36 . Powles , T . et al . MPDL3280A ( anti-PD-L1 ) treatment leads to clinical activity in metastatic bladder cancer . Nature 2014 ; 515:558 – 562 .
37 . Ye , Q . et al . CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor . Clin . Cancer Res . 2014 ; 20:44 – 55 .
38 . Le , D . T . et al . PD-1 blockade in tumors with mismatch repair deficiency . N . Engl . J . Med . 2015 . 19